Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
December 8, 2025BloodOpen Access

ANKRD26-related thrombocytopenia: Hematologic malignancy characteristics, clinical outcomes, and precursor states

View Full Paper
Ask AI
Bookmark
Share

Authors

LBLauren BanaszakSLSara E. LewisAFAlejandro Ferrer

Discussion

Loading...

Member takes

Overview

Observational analysis found high hematologic malignancy risk with age in patients with ANKRD26 variants, suggesting close monitoring is needed.

Key Points

  • Hematologic malignancy risk reaches 60% by age 80 in individuals with ANKRD26 variants.
  • Acute myeloid leukemia and chronic myeloid leukemia were significant findings among patients with thrombocytopenia.
  • Statistical analysis explored clinical and molecular features in an international cohort of ANKRD26-related thrombocytopenia.
  • Results indicate the need for surveillance strategies due to the high risk of relapse and malignancy.

Cite This Study

Banaszak et al. (2025) studied this question.

synapsesocial.com/papers/69362f7d4fa91c937236e4b6https://doi.org/10.1182/blood-2025-1440
View Full Paper
Ask AI
Bookmark
Share